AC Immune reports interim results from Phase 2 trial of ACI-7104.056

By Yahoo! Finance   |   1 year ago
AC Immune reports interim results from Phase 2 trial of ACI-7104.056

AC Immune reported positive interim data from the Phase 2 VacSYn trial of ACI-7104.056 for early Parkinson's disease treatment. Encouraging safety and immunogenicity results were observed, indicating potential benefits for patients. Future updates are expected in H1 2025.

Read More

Did you find this insightful?